SCHEMBL3925934

SCHEMBL3925934

Cc1cc(C)cc(CC(OCCO)c2[nH]c(=O)[nH]c(=O)c2C(C)C)c1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5199337 0.67 TYMP (0.37) PDE3BPDE3A
SCHEMBL6641589 0.64 MAPK8 (0.39)
SCHEMBL18933404 0.63 HCAR2 (0.34) PDE3BPDE3A
SCHEMBL501343 0.62 PDE3B (0.38) PDE3BPDE3A
SCHEMBL8681844 0.61
SCHEMBL501939 0.61 MAPT (0.37) PDE3BPDE3A
SCHEMBL9016367 0.60 TYMP (0.31)
SCHEMBL6086504 0.59 TYMP (0.37) PDE3BPDE3A
SCHEMBL10265038 0.58 ALDH1A1 (0.37) PDE3BPDE3A
SCHEMBL1484530 0.58 TYMP (0.33) PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3664811-A2 COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) 2020-06-17 EP claimed
WO-2019032749-A2 COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2019-02-14 WO claimed
WO-2013056003-A2 CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS YALE UNIVERSITY (US) 2013-04-18 WO claimed
WO-2009126293-A2 POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE YALE UNIVERSITY (US) 2009-10-15 WO claimed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023108089-A1 ARRDC1-MEDIATED MICROVESICLES (ARMMS) DEGRADING SYSTEM AND USES THEREOF Vesigen, Inc. (US) 2023-06-15 WO disclosed
EP-3897631-A1 TARGETED PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2021-10-27 EP disclosed
EP-3849987-A1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER F. Hoffmann-La Roche AG (CH) 2021-07-21 EP disclosed
EP-3774777-A2 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
EP-3774772-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
EP-3765026-A1 MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE Yale University (US) 2021-01-20 EP disclosed
EP-3700901-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2020-09-02 EP disclosed
WO-2017037142-A1 FOLDAMER HELIX BUNDLE-BASED MOLECULAR ENCAPSULATION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-03-09 WO disclosed
WO-2017011371-A1 MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS, INC (US) 2017-01-19 WO disclosed
WO-2016011280-A1 ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES TANGEN BIOSCIENCES, INC. (US) 2016-01-21 WO disclosed
EP-2802608-A2 COMPOUNDS&METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS&OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE Yale University (US) 2014-11-19 EP disclosed
WO-2013106643-A2 COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE YALE UNIVERSITY (US) 2013-07-18 WO disclosed
WO-2013056003-A2 CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS YALE UNIVERSITY (US) 2013-04-18 WO disclosed
WO-2009126293-A2 POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE YALE UNIVERSITY (US) 2009-10-15 WO disclosed
WO-2009005811-A1 NOVEL AZOLES AND RELATED DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) IN ANTIVIRAL THERAPY (HIV) YALE UNIVERSITY (US) 2009-01-08 WO disclosed